LUCA BIOLOGICS

LUCA Biologics is a biotechnology company developing a new class of living medicines targeting the vaginal microbiome to impact reproductive and urogenital health. Emerging from the lab of Dr. Jacques Ravel, Primary Investigator on the vaginal microbiome division of the NIH's Human Microbiome Project, our platform takes a metagenomic and metatranscriptomic approach to the identification, screening and validation of strains with therapeutic potential. Our pipeline includes therapeutics for urinary tract infection (UTI), preterm birth (PTB), bacterial vaginosis (BV), and infertility. LUCA Biologics is a Seed Health foundry company.